153 related articles for article (PubMed ID: 20347575)
1. Clinical development of drugs for epilepsy: a review of approaches in the United States and Europe.
Porter RJ; Baulac M; Nohria V
Epilepsy Res; 2010 May; 89(2-3):163-75. PubMed ID: 20347575
[TBL] [Abstract][Full Text] [Related]
2. External influences on protocol design.
Spilker B
Epilepsy Res Suppl; 1993; 10():115-24. PubMed ID: 8251087
[No Abstract] [Full Text] [Related]
3. European investigational antiepilepsy drug trials.
Sussman NM
Epilepsy Res Suppl; 1993; 10():149-55. PubMed ID: 8251090
[No Abstract] [Full Text] [Related]
4. Clinical trials performed for the new drug approval process in the United States: standard methods and alternative methods.
Browne TR
Epilepsy Res Suppl; 1993; 10():31-44. PubMed ID: 8251105
[No Abstract] [Full Text] [Related]
5. Antiepileptic drug development program.
Porter RJ
Prog Clin Biol Res; 1983; 127():53-66. PubMed ID: 6351101
[TBL] [Abstract][Full Text] [Related]
6. Moving goalposts--regulatory oversight of antibacterial drugs.
Brenner R; Ellis-Grosse EJ; Echols R
Nat Biotechnol; 2006 Dec; 24(12):1515-20. PubMed ID: 17160053
[TBL] [Abstract][Full Text] [Related]
7. Sources of variability in clinical trials of new drugs for epilepsy.
Leppik IE
Epilepsy Res Suppl; 1993; 10():157-66. PubMed ID: 8251091
[No Abstract] [Full Text] [Related]
8. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
9. Large clinical trials in epilepsy: funding by the NIH versus pharmaceutical industry.
Privitera M
Epilepsy Res; 2006 Jan; 68(1):52-6. PubMed ID: 16377139
[TBL] [Abstract][Full Text] [Related]
10. The domestic drug regulatory process: why time is of the essence.
Katz R
Epilepsy Res Suppl; 1993; 10():91-106. PubMed ID: 8251109
[No Abstract] [Full Text] [Related]
11. Promoting, improving and accelerating the drug development and approval processes.
Graul AI
Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297
[TBL] [Abstract][Full Text] [Related]
12. Promoting, improving and accelerating the drug development and approval processes.
Graul AI
Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
[TBL] [Abstract][Full Text] [Related]
13. [Contact and dialogue between drug companies and the global regulatory authorities throughout research and development phase].
Kock M; Thomsen MK
Ugeskr Laeger; 2003 Apr; 165(16):1649-52. PubMed ID: 12756820
[TBL] [Abstract][Full Text] [Related]
14. Industry perspectives on ICH guidelines.
Rockhold FW
Stat Med; 2002 Oct; 21(19):2949-57. PubMed ID: 12325111
[TBL] [Abstract][Full Text] [Related]
15. Delays in new drug applications in Japan and industrial R&D strategies.
Hirai Y; Kinoshita H; Kusama M; Yasuda K; Sugiyama Y; Ono S
Clin Pharmacol Ther; 2010 Feb; 87(2):212-8. PubMed ID: 19940847
[TBL] [Abstract][Full Text] [Related]
16. Statistical concepts in the planning and evaluation of drug safety from clinical trials in drug development: issues of international harmonization.
O'Neill RT
Stat Med; 1995 May 15-30; 14(9-10):117-27. PubMed ID: 7569506
[TBL] [Abstract][Full Text] [Related]
17. Protocol design.
Wilensky AJ
Epilepsy Res Suppl; 1993; 10():107-13. PubMed ID: 8251086
[No Abstract] [Full Text] [Related]
18. Study population selection.
Treiman DM
Epilepsy Res Suppl; 1993; 10():125-35. PubMed ID: 8251088
[No Abstract] [Full Text] [Related]
19. Review of the newer antiepileptic drugs.
Tidwell A; Swims M
Am J Manag Care; 2003 Mar; 9(3):253-76; quiz 277-9. PubMed ID: 12643343
[TBL] [Abstract][Full Text] [Related]
20. Patient recruitment and compliance issues in clinical trials.
Cramer JA
Epilepsy Res Suppl; 1993; 10():211-22. PubMed ID: 8251099
[No Abstract] [Full Text] [Related]
[Next] [New Search]